Recent submissions

  • Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy. 

    Huis In 't Veld, EA; Grünhagen, DJ; Deroose, JP; Nijsten, TEC; Wouters, MWJM; Verhoef, C; van Houdt, WJ; Hayes, AJ (2018-08)
    BACKGROUND: A small minority of patients present with locally advanced cutaneous Squamous Cell Carcinoma (cSCC). The aim of this study was to evaluate the effectiveness of Tumour necrosis factor α (TNF) and melphalan based ...
  • Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. 

    Bisogno, G; Jenney, M; Bergeron, C; Gallego Melcón, S; Ferrari, A; Oberlin, O; Carli, M; Stevens, M; Kelsey, A; De Paoli, A; Gaze, MN; Martelli, H; Devalck, C; Merks, JH; Ben-Arush, M; Glosli, H; Chisholm, J; Orbach, D; Minard-Colin, V; De Salvo, GL; European paediatric Soft tissue sarcoma Study Group (2018-08)
    BACKGROUND: Rhabdomyosarcoma is an aggressive tumour that can develop in almost any part of the body. Doxorubicin is an effective drug against rhabdomyosarcoma, but its role in combination with an established multidrug ...
  • Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. 

    Adams, C; Richmond, RC; Santos Ferreira, DL; Spiller, W; Tan, VY; Zheng, J; Wurtz, P; Donovan, JL; Hamdy, FC; Neal, DE; Lane, JA; Davey Smith, G; Relton, CL; Eeles, RA; Henderson, BE; Haiman, CA; Kote-Jarai, Z; Schumacher, FR; Amin Al Olama, A; Benlloch, S; Muir, K; Berndt, SI; Conti, DV; Wiklund, F; Chanock, SJ; Gapstur, SM; Stevens, VL; Tangen, CM; Batra, J; Clements, JA; Grönberg, H; Pashayan, N; Schleutker, J; Albanes, D; Wolk, A; West, CML; Mucci, LA; Cancel-Tassin, G; Koutros, S; Sørensen, KD; Maehle, L; Travis, RC; Hamilton, R; Ingles, SA; Rosenstein, BS; Lu, Y-J; Giles, GG; Kibel, AS; Vega, A; Kogevinas, M; Penney, KL; Park, JY; Stanford, JL; Cybulski, C; Nordestgaard, BG; Brenner, H; Maier, C; Kim, J; John, EM; Teixeira, MR; Neuhausen, SL; DeRuyck, K; Razack, A; Newcomb, LF; Lessel, D; Kaneva, RP; Usmani, N; Claessens, F; Townsend, P; Gago Dominguez, M; Roobol, MJ; Menegaux, F; Khaw, K-T; Cannon-Albright, LA; Pandha, H; Thibodeau, SN; Martin, RM (2018-10-23)
    BACKGROUND: Whether associations between circulating metabolites and prostate cancer are causal is unknown. We report on the largest study of metabolites and prostate cancer (2,291 cases and 2,661 controls) and appraise ...
  • Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study 

    Copson, ER; Maishman, TC; Tapper, WJ; Cutress, RI; Greville-Heygate, S; Altman, DG; Eccles, B; Gerty, S; Durcan, LT; Jones, L; Evans, DG; Thompson, AM; Pharoah, P; Easton, DF; Dunning, AM; Hanby, A; Lakhani, S; Eeles, R; Gilbert, FJ; Hamed, H; Hodgson, S; Simmonds, P; Stanton, L; Eccles, DM (Elsevier BV, 2018-02)
  • Germline variation at 8q24 and prostate cancer risk in men of European ancestry. 

    Matejcic, M; Saunders, EJ; Dadaev, T; Brook, MN; Wang, K; Sheng, X; Olama, AAA; Schumacher, FR; Ingles, SA; Govindasami, K; Benlloch, S; Berndt, SI; Albanes, D; Koutros, S; Muir, K; Stevens, VL; Gapstur, SM; Tangen, CM; Batra, J; Clements, J; Gronberg, H; Pashayan, N; Schleutker, J; Wolk, A; West, C; Mucci, L; Kraft, P; Cancel-Tassin, G; Sorensen, KD; Maehle, L; Grindedal, EM; Strom, SS; Neal, DE; Hamdy, FC; Donovan, JL; Travis, RC; Hamilton, RJ; Rosenstein, B; Lu, Y-J; Giles, GG; Kibel, AS; Vega, A; Bensen, JT; Kogevinas, M; Penney, KL; Park, JY; Stanford, JL; Cybulski, C; Nordestgaard, BG; Brenner, H; Maier, C; Kim, J; Teixeira, MR; Neuhausen, SL; De Ruyck, K; Razack, A; Newcomb, LF; Lessel, D; Kaneva, R; Usmani, N; Claessens, F; Townsend, PA; Dominguez, MG; Roobol, MJ; Menegaux, F; Khaw, K-T; Cannon-Albright, LA; Pandha, H; Thibodeau, SN; Schaid, DJ; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Wiklund, F; Chanock, SJ; Easton, DF; Eeles, RA; Kote-Jarai, Z; Conti, DV; Haiman, CA (2018-11-05)
    Chromosome 8q24 is a susceptibility locus for multiple cancers, including prostate cancer. Here we combine genetic data across the 8q24 susceptibility region from 71,535 prostate cancer cases and 52,935 controls of European ...
  • A Review of Prostate Cancer Genome-Wide Association Studies (GWAS). 

    Benafif, S; Kote-Jarai, Z; Eeles, RA; PRACTICAL Consortium (2018-08)
    Prostate cancer is the most common cancer in men in Europe and the United States. The genetic heritability of prostate cancer is contributed to by both rarely occurring genetic variants with higher penetrance and moderate ...
  • MRI measurement of residual cervical length after radical trachelectomy for cervical cancer and the risk of adverse pregnancy outcomes: a blinded imaging analysis. 

    Alvarez, RM; Biliatis, I; Rockall, A; Papadakou, E; Sohaib, SA; deSouza, NM; Butler, J; Nobbenhuis, M; Barton, D; Shepherd, JH; Ind, T (2018-12)
    OBJECTIVE: To determine the association between the residual cervix measured on postoperative MRI after radical vaginal trachelectomy (RVT) and adverse obstetrical outcomes. DESIGN: Observational study. SETTING: Referral ...
  • In Vivo Characterization of 4 68Ga-Labeled Multimeric RGD Peptides to Image αvβ3 Integrin Expression in 2 Human Tumor Xenograft Mouse Models. 

    Lobeek, D; Franssen, GM; Ma, MT; Wester, H-J; Decristoforo, C; Oyen, WJG; Boerman, OC; Terry, SYA; Rijpkema, M (2018-08)
    αvβ3 integrins play an important role in angiogenesis and cell migration in cancer and are highly expressed on the activated endothelial cells of newly formed blood vessels. Here, we compare the targeting characteristics ...
  • Comparison of Immediate versus Delayed DIEP Flap Reconstruction in Women Who Require Postmastectomy Radiotherapy. 

    O'Connell, RL; Di Micco, R; Khabra, K; Kirby, AM; Harris, PA; James, SE; Power, K; Ramsey, KWD; Rusby, JE (2018-09)
    BACKGROUND: The authors investigated aesthetic outcome and patient satisfaction in women who have undergone deep inferior epigastric artery perforator (DIEP) flap reconstruction in the setting of postmastectomy radiotherapy. ...
  • Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management. 

    Owen, C; Constantinidou, A; Miah, AB; Thway, K; Fisher, C; Benson, C; Zaidi, S; Messiou, C; VAN DER Graaf, WTA; Jones, RL (2018-09)
    BACKGROUND/AIM: Synovial sarcoma is a soft tissue sarcoma that tends to affect young adults. There are few reports on primary synovial sarcoma of the thyroid and the aim of this study was to document the clinical and ...
  • Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial. 

    Bhattacharya, IS; Haviland, JS; Kirby, AM; Kirwan, CC; Hopwood, P; Yarnold, JR; Bliss, JM; Coles, CE; IMPORT Trialists (2018-12-11)
    PURPOSE: IMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy versus whole-breast radiotherapy for local relapse and similar or reduced toxicity at 5 years. Comprehensive patient-reported ...
  • BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). 

    Kelly, JD; Tan, WS; Porta, N; Mostafid, H; Huddart, R; Protheroe, A; Bogle, R; Blazeby, J; Palmer, A; Cresswell, J; Johnson, M; Brough, R; Madaan, S; Andrews, S; Cruickshank, C; Burnett, S; Maynard, L; Hall, E; BOXIT Investigators (2018-09-29)
    BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. OBJECTIVE: To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk ...
  • Novel adaptive beam-dependent margins for additional OAR sparing. 

    Tsang, HS; Kamerling, CP; Ziegenhein, P; Nill, S; Oelfke, U (2018-10-29)
    Margins are employed in radiotherapy treatment planning to mitigate the dosimetric effects of geometric uncertainties for the clinical target volume (CTV). Unfortunately, whilst the use of margins can increase the probability ...
  • Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. 

    Mancuso, N; Gayther, S; Gusev, A; Zheng, W; Penney, KL; Kote-Jarai, Z; Eeles, R; Freedman, M; Haiman, C; Pasaniuc, B; PRACTICAL consortium (2018-10-04)
    Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than 100 risk regions, most of the risk genes at these regions remain largely unknown. Here we integrate the largest PrCa GWAS ...
  • Affibody-based PET imaging to guide EGFR-targeted cancer therapy in head and neck squamous cell cancer models. 

    Burley, TA; Pieve, CD; Martins, CD; Ciobota, DM; Allott, L; Oyen, WJG; Harrington, KJ; Smith, G; Kramer-Marek, G (2018-09-13)
    In head and neck squamous cell carcinoma (HNSCC), the human epidermal growth factor receptor 1 (EGFR) is the dominant signaling molecule among all members of the family. So far, cetuximab is the only approved anti-EGFR mAb ...
  • Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. 

    Chew, W; Benson, C; Thway, K; Hayes, A; Miah, A; Zaidi, S; Lee, ATJ; Messiou, C; Fisher, C; van der Graaf, WT; Jones, RL (2018-09-05)
    BACKGROUND: Sclerosing epithelioid fibrosarcoma (SEF) is a very rare soft tissue sarcoma subtype. Clinically it is an aggressive tumour; however, to our knowledge there are no published reports regarding the efficacy of ...
  • Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. 

    Pender, A; Davis, EJ; Chauhan, D; Messiou, C; Al-Muderis, O; Thway, K; Fisher, C; Zaidi, S; Miah, A; Judson, I; van der Graaf, W; Keedy, VL; Benson, C; Jones, RL (2018-08-20)
    The outcome for patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options. Synovial sarcoma is a rare type of sarcoma, predominantly affecting adolescents and young adults. Following ...
  • The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers 

    Amos, CI; Dennis, J; Wang, Z; Byun, J; Schumacher, FR; Gayther, SA; Casey, G; Hunter, DJ; Sellers, TA; Gruber, SB; Dunning, AM; Michailidou, K; Fachal, L; Doheny, K; Spurdle, AB; Li, Y; Xiao, X; Romm, J; Pugh, E; Coetzee, GA; Hazelett, DJ; Bojesen, SE; Caga-Anan, C; Haiman, CA; Kamal, A; Luccarini, C; Tessier, D; Vincent, D; Bacot, F; Van Den Berg, DJ; Nelson, S; Demetriades, S; Goldgar, DE; Couch, FJ; Forman, JL; Giles, GG; Conti, DV; Bickeböller, H; Risch, A; Waldenberger, M; Brüske-Hohlfeld, I; Hicks, BD; Ling, H; McGuffog, L; Lee, A; Kuchenbaecker, K; Soucy, P; Manz, J; Cunningham, JM; Butterbach, K; Kote-Jarai, Z; Kraft, P; FitzGerald, L; Lindström, S; Adams, M; McKay, JD; Phelan, CM; Benlloch, S; Kelemen, LE; Brennan, P; Riggan, M; O'Mara, TA; Shen, H; Shi, Y; Thompson, DJ; Goodman, MT; Nielsen, SF; Berchuck, A; Laboissiere, S; Schmit, SL; Shelford, T; Edlund, CK; Taylor, JA; Field, JK; Park, SK; Offit, K; Thomassen, M; Schmutzler, R; Ottini, L; Hung, RJ; Marchini, J; Amin Al Olama, A; Peters, U; Eeles, RA; Seldin, MF; Gillanders, E; Seminara, D; Antoniou, AC; Pharoah, PDP; Chenevix-Trench, G; Chanock, SJ; Simard, J; Easton, DF (2017-01)
  • Blood lipids and prostate cancer: a Mendelian randomization analysis. 

    Bull, CJ; Bonilla, C; Holly, JM; Perks, CM; Davies, N; Haycock, P; Yu, OH; Richards, JB; Eeles, R; Easton, D; Kote-Jarai, Z; Amin Al Olama, A; Benlloch, S; Muir, K; Giles, GG; MacInnis, RJ; Wiklund, F; Gronberg, H; Haiman, CA; Schleutker, J; Nordestgaard, BG; Travis, RC; Neal, D; Pashayan, N; Khaw, KT; Stanford, JL; Blot, WJ; Thibodeau, S; Maier, C; Kibel, AS; Cybulski, C; Cannon-Albright, L; Brenner, H; Park, J; Kaneva, R; Batra, J; Teixeira, MR; Micheal, A; Pandha, H; Smith, GD; Lewis, SJ; Martin, RM (2016-06)
    Genetic risk scores were used as unconfounded instruments for specific lipid traits (Mendelian randomization) to assess whether circulating lipids causally influence prostate cancer risk. Data from 22,249 prostate cancer ...
  • Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. 

    Silvestri, V; Barrowdale, D; Mulligan, AM; Neuhausen, SL; Fox, S; Karlan, BY; Mitchell, G; James, P; Thull, DL; Zorn, KK; Carter, NJ; Nathanson, KL; Domchek, SM; Rebbeck, TR; Ramus, SJ; Nussbaum, RL; Olopade, OI; Rantala, J; Yoon, SY; Caligo, MA; Spugnesi, L; Bojesen, A; Pedersen, IS; Thomassen, M; Jensen, UB; Toland, AE; Senter, L; Andrulis, IL; Glendon, G; Hulick, PJ; Imyanitov, EN; Greene, MH; Mai, PL; Singer, CF; Rappaport-Fuerhauser, C; Kramer, G; Vijai, J; Offit, K; Robson, M; Lincoln, A; Jacobs, L; Machackova, E; Foretova, L; Navratilova, M; Vasickova, P; Couch, FJ; Hallberg, E; Ruddy, KJ; Sharma, P; Kim, SW; Teixeira, MR; Pinto, P; Montagna, M; Matricardi, L; Arason, A; Johannsson, OT; Barkardottir, RB; Jakubowska, A; Lubinski, J; Izquierdo, A; Pujana, MA; Balmaña, J; Diez, O; Ivady, G; Papp, J; Olah, E; Kwong, A; Nevanlinna, H; Aittomäki, K; Perez Segura, P; Caldes, T; Van Maerken, T; Poppe, B; Claes, KB; Isaacs, C; Elan, C; Lasset, C; Stoppa-Lyonnet, D; Barjhoux, L; Belotti, M; Meindl, A; Gehrig, A; Sutter, C; Engel, C; Niederacher, D; Steinemann, D; Hahnen, E; Kast, K; Arnold, N; Varon-Mateeva, R; Wand, D; Godwin, AK; Evans, DG; Frost, D; Perkins, J; Adlard, J; Izatt, L; Platte, R; Eeles, R; Ellis, S; Hamann, U; Garber, J; Fostira, F; Fountzilas, G; Pasini, B; Giannini, G; Rizzolo, P; Russo, A; Cortesi, L; Papi, L; Varesco, L; Palli, D; Zanna, I; Savarese, A; Radice, P; Manoukian, S; Peissel, B; Barile, M; Bonanni, B; Viel, A; Pensotti, V; Tommasi, S; Peterlongo, P; Weitzel, JN; Osorio, A; Benitez, J; McGuffog, L; Healey, S; Gerdes, AM; Ejlertsen, B; Hansen, TV; Steele, L; Ding, YC; Tung, N; Janavicius, R; Goldgar, DE; Buys, SS; Daly, MB; Bane, A; Terry, MB; John, EM; Southey, M; Easton, DF; Chenevix-Trench, G; Antoniou, AC; Ottini, L (2016-01)
    BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using ...

View more